scispace - formally typeset
E

Eva Harris

Researcher at University of California, Berkeley

Publications -  357
Citations -  26475

Eva Harris is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Dengue virus & Dengue fever. The author has an hindex of 84, co-authored 332 publications receiving 22718 citations.

Papers
More filters
Journal ArticleDOI

In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection.

TL;DR: The anti-asthmatic pranlukast is proposed as a drug candidate against DENV, ZikV, and CHIKV, supporting further in vitro and in vivo assessment of the potential of this and other lead compounds that exhibited good affinity scores in silico as therapeutic agents or scaffolds for the development of new drugs against arboviral diseases.
Journal ArticleDOI

Innovative low cost technologies for biomedical research and diagnosis in developing countries

Josefina Coloma, +1 more
- 11 Nov 2004 - 
TL;DR: Researchers in the developed world can learn much from the ingenuity and passion of colleagues in developing countries, as working in resource poor settings fosters creativity and a mindset for conservation and better management of resources.
Journal ArticleDOI

Prevalence and Clinical Profile of Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Farmworkers, California, USA, June-November 2020.

TL;DR: In this paper, the authors conducted prospective surveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and antibody prevalence among farmworkers in Salinas Valley, California, during June 15-November 30, 2020.
Journal ArticleDOI

Influenza and dengue virus co-infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia

TL;DR: This study shows that co‐infection with influenza and DENV impairs host responses, which fail to control DENV titers and instead, induce severe lung damage, and identifies key inflammatory pathways and monocyte function as targets for future therapies that may limit immunopathology in co‐ Infected patients.